BRIEF-Gilead Says Further Analyses Of Phase 3 ASSURE Study Shows Sustained ALP Normalization

Gilead Sciences

Gilead Sciences

GILD

0.00

May 27 (Reuters) - Gilead Sciences, Inc GILD.O:

  • GILEAD: FURTHER ANALYSES OF PHASE 3 ASSURE STUDY DEMONSTRATE SUSTAINED ALP NORMALIZATION

  • GILEAD - REPORTS LIVDELZI ACHIEVES HIGH AND SUSTAINED ALP NORMALIZATION IN PBC PATIENTS

  • GILEAD - LIVDELZI GENERALLY WELL TOLERATED WITH NO NEW SAFETY SIGNALS OVER TWO YEARS

Source text: ID:nBw2mqXQTa

Further company coverage: GILD.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.